



Clinical trial results:

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Summary

EudraCT number	2018-004614-18
Trial protocol	AT HU FR GB DE NL ES PL DK BE SK LT CZ LV HR IT RO
Global end of trial date	02 October 2023

Results information

Result version number	v1
This version publication date	01 September 2024
First version publication date	01 September 2024

Trial information

Trial identification

Sponsor protocol code	I6T-MC-AMAM
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03926130
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 16590

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 October 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	02 October 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 July 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Türkiye: 41
Country: Number of subjects enrolled	United States: 117
Country: Number of subjects enrolled	Czechia: 57
Country: Number of subjects enrolled	Russian Federation: 86
Country: Number of subjects enrolled	Austria: 10
Country: Number of subjects enrolled	Latvia: 3
Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	Korea, Republic of: 60
Country: Number of subjects enrolled	China: 164
Country: Number of subjects enrolled	Brazil: 58
Country: Number of subjects enrolled	Poland: 161
Country: Number of subjects enrolled	Slovakia: 19
Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	Lithuania: 5
Country: Number of subjects enrolled	Serbia: 21
Country: Number of subjects enrolled	Croatia: 7
Country: Number of subjects enrolled	Argentina: 2
Country: Number of subjects enrolled	Romania: 13
Country: Number of subjects enrolled	Hungary: 34
Country: Number of subjects enrolled	Japan: 28

Country: Number of subjects enrolled	Ukraine: 88
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Switzerland: 7
Country: Number of subjects enrolled	India: 25
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	Canada: 35
Country: Number of subjects enrolled	Belgium: 9
Country: Number of subjects enrolled	Denmark: 2
Country: Number of subjects enrolled	Italy: 8
Country: Number of subjects enrolled	Mexico: 7
Country: Number of subjects enrolled	Israel: 15
Country: Number of subjects enrolled	Australia: 18
Country: Number of subjects enrolled	Germany: 38
Worldwide total number of subjects	1158
EEA total number of subjects	381

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	6
Adults (18-64 years)	1119
From 65 to 84 years	33
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Not applicable

Pre-assignment

Screening details:

Not applicable

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion, Solution for injection in pre-filled syringe
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received Placebo IV or SC Q4W. Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study.

Arm title	Mirikizumab
------------------	-------------

Arm description:

Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

Arm type	Experimental
Investigational medicinal product name	Mirikizumab
Investigational medicinal product code	
Other name	LY3074828
Pharmaceutical forms	Solution for infusion, Suspension for injection in pre-filled syringe
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

Arm title	Ustekinumab
------------------	-------------

Arm description:

Participants received 6 milligrams per kilogram (mg/kg) Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W)

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion, Solution for injection in pre-filled syringe
Routes of administration	Intravenous use, Subcutaneous use
Dosage and administration details:	
Participants received 6 mg/kg Ustekinumab IV for one dose, then 90 mg SC Q8W	
Arm title	Mirikizumab (Adolescents)

Arm description:

Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

Arm type	Experimental
Investigational medicinal product name	Mirikizumab
Investigational medicinal product code	
Other name	LY3074828
Pharmaceutical forms	Solution for infusion, Suspension for injection in pre-filled syringe
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received open label 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

Number of subjects in period 1	Placebo	Mirikizumab	Ustekinumab
Started	212	631	309
Received At Least One Dose of Study Drug	211	630	309
Placebo Non-Responders at Week 12	85 ^[1]	0 ^[2]	0 ^[3]
Completed	159	561	271
Not completed	53	70	38
Adverse event, serious fatal	2	-	1
Consent withdrawn by subject	20	28	18
Physician decision	3	2	1
Adverse event, non-fatal	9	11	2
As Reported by Investigator	2	6	6
Pregnancy	2	2	1
Withdrawal by Subject	-	-	-
Study Terminated by Sponsor	1	1	-
Lost to follow-up	-	7	1
Disposition Not Captured	-	2	1
Lack of efficacy	14	11	7

Number of subjects in period 1	Mirikizumab (Adolescents)
Started	6
Received At Least One Dose of Study Drug	6
Placebo Non-Responders at Week 12	0 ^[4]

Completed	4
Not completed	2
Adverse event, serious fatal	-
Consent withdrawn by subject	-
Physician decision	-
Adverse event, non-fatal	-
As Reported by Investigator	-
Pregnancy	-
Withdrawal by Subject	1
Study Terminated by Sponsor	-
Lost to follow-up	-
Disposition Not Captured	-
Lack of efficacy	1

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestone only shows Placebo Non-Responders; number should not be included again in count.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestone only shows Placebo Non-Responders; number should not be included again in count.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestone only shows Placebo Non-Responders; number should not be included again in count.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestone only shows Placebo Non-Responders; number should not be included again in count.

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline.	
Reporting group title	Mirikizumab
Reporting group description:	
Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W	
Reporting group title	Ustekinumab
Reporting group description:	
Participants received 6 milligrams per kilogram (mg/kg) Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W)	
Reporting group title	Mirikizumab (Adolescents)
Reporting group description:	
Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W	

Reporting group values	Placebo	Mirikizumab	Ustekinumab
Number of subjects	212	631	309
Age categorical			
Units: Subjects			
<=18 years	4	11	6
Between 18 and 65 years	205	598	295
>=65 years	3	22	8
Gender categorical			
Units: Subjects			
Female	87	274	161
Male	125	357	148
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	4	8	6
Not Hispanic or Latino	16	58	25
Unknown or Not Reported	192	565	278
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	2	2	2
Asian	44	158	78
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	5	12	8
White	155	448	219
More than one race	0	3	1
Unknown or Not Reported	6	8	1
Region of Enrollment			
Units: Subjects			
United States	20	66	31

Czechia	11	29	17
Russia	22	44	20
Austria	0	7	3
Latvia	0	1	2
Netherlands	1	2	1
South Korea	7	40	11
China	31	90	43
Brazil	11	29	18
Poland	28	83	47
Slovakia	2	10	7
France	3	3	1
Lithuania	1	3	1
Serbia	8	7	6
Croatia	1	6	0
Argentina	0	2	0
Romania	1	10	2
Hungary	5	19	10
Japan	4	11	13
Ukraine	12	43	33
United Kingdom	0	4	1
Switzerland	1	3	3
India	2	13	10
Spain	1	3	0
Canada	8	19	8
Turkey	6	28	7
Belgium	2	5	2
Denmark	0	2	0
Italy	3	4	0
Mexico	1	4	2
Israel	4	9	2
Australia	8	10	0
Germany	8	22	8

Reporting group values	Mirikizumab (Adolescents)	Total	
Number of subjects	6	1158	
Age categorical			
Units: Subjects			
<=18 years	6	27	
Between 18 and 65 years	0	1098	
>=65 years	0	33	
Gender categorical			
Units: Subjects			
Female	3	525	
Male	3	633	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	18	
Not Hispanic or Latino	0	99	
Unknown or Not Reported	6	1041	
Race (NIH/OMB)			
Units: Subjects			

American Indian or Alaska Native	0	6	
Asian	2	282	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	0	25	
White	4	826	
More than one race	0	4	
Unknown or Not Reported	0	15	
Region of Enrollment			
Units: Subjects			
United States	0	117	
Czechia	0	57	
Russia	0	86	
Austria	0	10	
Latvia	0	3	
Netherlands	0	4	
South Korea	2	60	
China	0	164	
Brazil	0	58	
Poland	3	161	
Slovakia	0	19	
France	0	7	
Lithuania	0	5	
Serbia	0	21	
Croatia	0	7	
Argentina	0	2	
Romania	0	13	
Hungary	0	34	
Japan	0	28	
Ukraine	0	88	
United Kingdom	0	5	
Switzerland	0	7	
India	0	25	
Spain	0	4	
Canada	0	35	
Turkey	0	41	
Belgium	0	9	
Denmark	0	2	
Italy	1	8	
Mexico	0	7	
Israel	0	15	
Australia	0	18	
Germany	0	38	

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline.	
Reporting group title	Mirikizumab
Reporting group description: Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W	
Reporting group title	Ustekinumab
Reporting group description: Participants received 6 milligrams per kilogram (mg/kg) Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W)	
Reporting group title	Mirikizumab (Adolescents)
Reporting group description: Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W	
Subject analysis set title	900 mg Mirikizumab IV Q4W
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 900 mg Mirikizumab IV Q4W for 3 doses	
Subject analysis set title	300 mg Mirikizumab SC Q4W
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 300 mg Mirikizumab SC Q4W	

Primary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) ^[1]
End point description: Clinical response by Patient Reported Outcome (PRO) defined as $\geq 30\%$ decrease in stool frequency (SF) and/or abdominal pain (AP) & neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Endoscopic response defined as $\geq 50\%$ reduction from baseline in total Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; >2 cm=3); extent of ulcerated surface (none=0; <10%=1; 10% to 30%=2; >30%=3); extent of affected surface (none=0; <50%=1; 50% to 75%=2; >75%=3); presence & type of narrowing (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.	
End point type	Primary
End point timeframe: Week 12 to Week 52	

Analysis Population Description (APD): All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	9.0 (5.1 to 13.0)	38.0 (34.0 to 42.0)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	28.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	23
upper limit	34.4

Primary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab) ^[2]
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical response by PRO defined as $\geq 30\%$ decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Clinical remission defined as Crohn's Disease Activity Index (CDAI) total score <150 . The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible) and 5 physician-reported/laboratory items (physical signs and a laboratory parameter [hematocrit]). Total score range of 0 to 600 points.

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 12 to Week 52

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	19.6 (14.1 to 25.1)	45.4 (41.4 to 49.5)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	25.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.8
upper limit	32.7

Secondary: Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab) ^[3]
-----------------	--------------------------------------------------------------------------------------------------------------------

End point description:

Endoscopic Response defined as $\geq 50\%$ reduction from baseline in total SES-CD score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; > 2 cm = 3); extent of ulcerated surface (none = 0; $< 10\%$ = 1; 10% to 30% = 2; $> 30\%$ = 3); extent of affected surface (none = 0; $< 50\%$ = 1; 50% to 75% = 2; $> 75\%$ = 3); presence & type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

APD: All randomized participants in the Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	12.6 (8.0 to 17.2)	32.5 (28.7 to 36.3)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	19.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.7
upper limit	25.6

Secondary: Percentage of Adult Participants Achieving Endoscopic Response at Week 52

End point title	Percentage of Adult Participants Achieving Endoscopic Response at Week 52 ^[4]
-----------------	------------------------------------------------------------------------------------------

End point description:

Endoscopic Response defined as $\geq 50\%$ reduction from baseline in total SES-CD score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; > 2 cm = 3); extent of ulcerated surface (none = 0; $< 10\%$ = 1; 10% to 30% = 2; $> 30\%$ = 3); extent of affected surface (none = 0; $< 50\%$ = 1; 50% to 75% = 2; $> 75\%$ = 3); presence & type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

APD: All randomized participants who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug per protocol.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 52

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo, Mirikizumab, Ustekinumab arms.

End point values	Placebo	Mirikizumab	Ustekinumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	199	579	287	
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	9.0 (5.1 to 13.0)	48.4 (44.3 to 52.4)	46.3 (40.6 to 52.1)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	39.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.4
upper limit	44.8

Statistical analysis title	Statistical Analysis 2
Comparison groups	Mirikizumab v Ustekinumab
Number of subjects included in analysis	866
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.513623
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	9.3

Secondary: Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab) ^[5]
-----------------	-------------------------------------------------------------------------------------------------------------------

End point description:

Clinical remission defined as CDAI total score <150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter [hematocrit]). Total score range of 0 to 600 points.

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	25.1 (19.1 to 31.2)	37.7 (33.7 to 41.6)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001431
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	12.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.3
upper limit	19.6

Secondary: Percentage of Adult Participants Achieving Clinical Remission at Week 52

End point title	Percentage of Adult Participants Achieving Clinical Remission at Week 52 ^[6]
-----------------	-----------------------------------------------------------------------------------------

End point description:

Clinical remission defined as CDAI total score <150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5

physician-reported/laboratory items (physical signs and a laboratory parameter [hematocrit]). Total score range of 0 to 600 points.

APD: All randomized participants who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug per protocol.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 52

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo, Mirikizumab, Ustekinumab arms.

End point values	Placebo	Mirikizumab	Ustekinumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	199	579	287	
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	19.6 (14.1 to 25.1)	54.1 (50.0 to 58.1)	48.4 (42.7 to 54.2)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	34.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	27.7
upper limit	41.4

Statistical analysis title	Statistical Analysis 2
Comparison groups	Mirikizumab v Ustekinumab
Number of subjects included in analysis	866
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	< 0.0001
Method	Z test
Parameter estimate	Risk difference (RD)
Point estimate	5.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	12.8

Secondary: Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab) ^[7]
-----------------	---------------------------------------------------------------------------------------------------------------------

End point description:

Endoscopic remission SES-CD ≤ 4 is defined as SES-CD Total Score ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 . SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; > 2 cm = 3); extent of ulcerated surface (none = 0; $< 10\%$ = 1; 10% to 30% = 2; $> 30\%$ = 3); extent of affected surface (none = 0; $< 50\%$ = 1; 50% to 75% = 2; $> 75\%$ = 3); presence & type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	4.0 (1.3 to 6.7)	10.9 (8.3 to 13.4)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Mirikizumab v Placebo
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003414
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	6.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	3.2
upper limit	10.5

Secondary: Change from Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)

End point title	Change from Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab) ^[8]
-----------------	--------------------------------------------------------------------------------------------------------------------------------------

End point description:

The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: score on a scale				
least squares mean (standard error)	-1.58 (\pm 0.168)	-2.44 (\pm 0.099)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000011
Method	ANCOVA
Parameter estimate	Least Squares (LS) Mean Difference (Net)
Point estimate	-0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.24
upper limit	-0.48

Secondary: Change from Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)

End point title	Change from Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab) ^[9]
-----------------	---------------------------------------------------------------------------------------------------------------

End point description:

The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: score on a scale				
least squares mean (standard error)	-1.23 (\pm 0.180)	-3.24 (\pm 0.106)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LSMean Difference (Net)
Point estimate	-2.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.42
upper limit	-1.6

Secondary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab) ^[10]
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical Response by PRO defined as $\geq 30\%$ decrease in SF and/or AP & neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Clinical Remission by PRO defined as defined as SF ≤ 3 and not worse than baseline (as per Bristol Stool Scale Category 6 or 7) and AP ≤ 1 and no worse than baseline.

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 to Week 52

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	19.6 (14.1 to 25.1)	45.4 (41.4 to 49.5)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	25.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.9
upper limit	32.6

Secondary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab) ^[11]
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical Response by PRO defined as $\geq 30\%$ decrease in SF and/or AP & neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Endoscopic remission SES-CD ≤ 4 is defined as SES-CD Total Score ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 . SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; > 2 cm=3); extent of ulcerated surface (none = 0; $< 10\%$ = 1; 10% to 30% = 2; $> 30\%$ = 3); extent of affected surface (none = 0; $< 50\%$ = 1; 50% to 75% = 2; $> 75\%$ = 3); presence & type of narrowing (none =0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 to Week 52

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	2.0 (0.1 to 4.0)	15.9 (12.9 to 18.9)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	13.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.2
upper limit	17.4

Secondary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free AND either in Clinical Remission or Endoscopic Remission at

Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free AND either in Clinical Remission or Endoscopic Remission at Week 52 (Placebo and Mirikizumab) ^[12]
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

APD: Zero participants analyzed. Analysis not completed as FDA recommended modification of endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 to Week 52

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis planned only on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[13]	0 ^[14]		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	(to)	(to)		

Notes:

[13] - Zero participants analyzed. Analysis not completed as FDA recommended modification of endpoint.

[14] - Zero participants analyzed. Analysis not completed as FDA recommended modification of endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab) ^[15]
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical response by PRO defined as $\geq 30\%$ decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Clinical remission defined as CDAI total score < 150 . The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter [hematocrit]). Total score range of 0 to 600 points.

Corticosteroid-free clinical remission by CDAI is defined as achieving clinical remission by CDAI at Week 52 and being corticosteroid free from Week 40 to Week 52.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 to Week 52

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	18.6 (13.2 to 24.0)	43.7 (39.7 to 47.7)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	25
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.2
upper limit	31.8

Secondary: Change from Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)

End point title	Change from Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab) ^[16]
-----------------	-----------------------------------------------------------------------------------------------------------------------------

End point description:

Change from baseline in CRP

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: milligram per liter (mg/L)				
least squares mean (standard error)	-0.08 (± 0.087)	-0.93 (± 0.051)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LSMean Difference (Net)
Point estimate	-0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.05
upper limit	-0.65

Secondary: Change from Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)

End point title	Change from Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab) ^[17]
-----------------	-----------------------------------------------------------------------------------------------------------------------

End point description:

Change from baseline in Fecal Calprotectin

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug and had baseline fecal calprotectin.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: micrograms per gram (µg/g)				
least squares mean (standard error)	-0.19 (± 0.117)	-1.41 (± 0.067)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Mirikizumab v Placebo
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LSMean Difference (Net)
Point estimate	-1.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.48
upper limit	-0.95

Secondary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab) ^[18]
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥7 (or ≥4 for isolated ileal disease) and received at least one dose of study drug and had at least one EIM at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 to Week 52

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	41	132		
Units: percentage of participants				
number (not applicable)	14.6	43.2		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Mirikizumab v Placebo
Number of subjects included in analysis	173
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants with Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants with Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab) ^[19]
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥7 (or ≥4 for isolated ileal disease) and received at least one dose of study drug and had at least one draining cutaneous fistulae at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 to Week 52

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	38		
Units: percentage of participants				
arithmetic mean (confidence interval 95%)	16.7 (0.0 to 33.9)	21.1 (8.1 to 34.0)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Mirikizumab v Placebo
Number of subjects included in analysis	56
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.732715
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	4.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18
upper limit	26.1

Secondary: Change from Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)

End point title	Change from Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab) ^[20]
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

The IBDQ is a 32-item patient completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Scores range from 32 to 224; a higher score indicates a better quality of life.

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: score on a scale				
least squares mean (standard error)	15.9 (\pm 2.316)	43.82 (\pm 1.365)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LSMean Difference (Net)
Point estimate	27.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	22.67
upper limit	33.18

Secondary: Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab

End point title	Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab
End point description:	
PopPK: AUC of Mirikizumab	
APD: All randomized participants who received at least one dose of study drug and had evaluable PK data.	
End point type	Secondary
End point timeframe:	
Week 4, 8, 12, 16, 24, 36: Predose; Week 4, Day 1: Postdose; Week 52	

End point values	900 mg Mirikizumab IV Q4W	300 mg Mirikizumab SC Q4W		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	711	711		
Units: micrograms*day per milliliter(ug*day/mL)				
geometric mean (geometric coefficient of variation)	1820 (\pm 38.1)	220 (\pm 55.9)		

Statistical analyses

No statistical analyses for this end point

Post-hoc: Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab) ^[21]
-----------------	----------------------------------------------------------------------------------------------------------------------

End point description:

Endoscopic remission SES-CD ≤ 4 is defined as SES-CD Total Score ≤ 4 and at least a 2-point reduction from baseline and no subscore >1 in any individual variable. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; >2 cm = 3); extent of ulcerated surface (none = 0; $<10\%$ = 1; 10% to 30% = 2; $>30\%$ = 3); extent of affected surface (none = 0; $<50\%$ = 1; 50% to 75% = 2; $>75\%$ = 3); presence & type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

End point type	Post-hoc
----------------	----------

End point timeframe:

Week 12

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 99.5%)	7.0 (1.9 to 12.1)	17.6 (13.2 to 22.1)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab
Number of subjects included in analysis	778
Analysis specification	Post-hoc
Analysis type	superiority
P-value	= 0.000213
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	10.6

Confidence interval	
level	Other: 99.5 %
sides	2-sided
lower limit	4.1
upper limit	17.2

Post-hoc: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)

End point title	Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab) ^[22]
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical Response by PRO defined as $\geq 30\%$ decrease in SF and/or AP & neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Endoscopic remission SES-CD ≤ 4 is defined as SES-CD Total Score ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence & size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; > 2 cm=3); extent of ulcerated surface (none = 0; $< 10\%$ = 1; 10% to 30% = 2; $> 30\%$ = 3); extent of affected surface (none = 0; $< 50\%$ = 1; 50% to 75% = 2; $> 75\%$ = 3); presence & type of narrowing (none =0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

End point type	Post-hoc
----------------	----------

End point timeframe:

Week 12 to Week 52

APD: All randomized participants in Placebo and Mirikizumab arms who have baseline SES-CD ≥ 7 (or ≥ 4 for isolated ileal disease) and received at least one dose of study drug.

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per Protocol, analysis only performed on Placebo and Mirikizumab arms.

End point values	Placebo	Mirikizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	579		
Units: percentage of participants				
arithmetic mean (confidence interval 99.5%)	4.0 (0.1 to 7.9)	23.5 (18.5 to 28.4)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Mirikizumab

Number of subjects included in analysis	778
Analysis specification	Post-hoc
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	19.4
Confidence interval	
level	Other: 99.5 %
sides	2-sided
lower limit	13.1
upper limit	25.7

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline through follow up (up to 68 weeks)

Adverse event reporting additional description:

All randomized participants who received one dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received Placebo IV or SC Q4W

Reporting group title	Placebo Non-Responders
-----------------------	------------------------

Reporting group description:

Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study.

Reporting group title	Mirikizumab
-----------------------	-------------

Reporting group description:

Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

Reporting group title	Ustekinumab
-----------------------	-------------

Reporting group description:

Participants received 6 mg/kg Ustekinumab IV for one dose, then 90 mg SC Q8W

Reporting group title	Mirikizumab (Adolescents)
-----------------------	---------------------------

Reporting group description:

Participants received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

Serious adverse events	Placebo	Placebo Non-Responders	Mirikizumab
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 126 (25.40%)	12 / 85 (14.12%)	65 / 630 (10.32%)
number of deaths (all causes)	1	1	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
breast cancer			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colorectal adenoma			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
haemorrhage			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypotension			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peripheral arterial occlusive disease			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
anal fistula repair			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ileectomy			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
abortion spontaneous			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
oedema			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyrexia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
swelling			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
anaphylactic reaction			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infusion related hypersensitivity reaction			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	1 / 85 (1.18%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
chronic obstructive pulmonary disease			

alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	1 / 85 (1.18%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
panic disorder			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
anastomotic stenosis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural haemorrhage			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
procedural intestinal perforation			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	1 / 85 (1.18%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tibia fracture			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
hydrocele			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed ^[1]	0 / 77 (0.00%)	0 / 48 (0.00%)	0 / 356 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
atrial fibrillation			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
angina pectoris			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac arrest			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardio-respiratory arrest			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac failure acute			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
cerebrovascular accident			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
headache			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
loss of consciousness			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myoclonic epilepsy			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
syncope			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
anaemia macrocytic			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
anaemia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	2 / 630 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
sudden hearing loss			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	1 / 85 (1.18%)	2 / 630 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
anal fistula			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	4 / 126 (3.17%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal pain upper			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal pain lower alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	1 / 85 (1.18%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
anorectal disorder alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
enterocolonic fistula alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
enteritis alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diarrhoea haemorrhagic alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastrointestinal disorder alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

crohn's disease				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	12 / 126 (9.52%)	4 / 85 (4.71%)	12 / 630 (1.90%)	
occurrences causally related to treatment / all	3 / 12	1 / 4	2 / 12	
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0	
colitis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
diarrhoea				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	2 / 630 (0.32%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
gastrointestinal perforation				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
ileal stenosis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
ileus				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 126 (0.00%)	1 / 85 (1.18%)	2 / 630 (0.32%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
inguinal hernia				
alternative dictionary used: MedDRA 26.1				

subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
large intestine perforation alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	2 / 630 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intestinal perforation alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	1 / 85 (1.18%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intestinal obstruction alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	1 / 85 (1.18%)	3 / 630 (0.48%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
nausea alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
obstruction gastric alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancreatitis acute alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

rectal stenosis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small intestinal obstruction			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	4 / 630 (0.63%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
subileus			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
bile duct stone			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	2 / 126 (1.59%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis acute			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholangitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
hydronephrosis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chondrocalcinosis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral disc degeneration			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sacroiliitis			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
abdominal abscess			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	2 / 630 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
anal abscess			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	2 / 630 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abscess limb			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abscess intestinal			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
covid-19			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	2 / 630 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
covid-19 pneumonia			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
appendicitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
clostridium difficile colitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastroenteritis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fournier's gangrene			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
clostridium difficile infection			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

liver abscess			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia aspiration			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritonitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pelvic abscess			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
salpingitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed ^[2]	0 / 49 (0.00%)	1 / 37 (2.70%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
septic shock			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malnutrition			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Ustekinumab	Mirikizumab (Adolescents)	
Total subjects affected by serious adverse events			
subjects affected / exposed	35 / 309 (11.33%)	0 / 6 (0.00%)	
number of deaths (all causes)	1	0	

number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
breast cancer			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
colorectal adenoma			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
haemorrhage			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypotension			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
peripheral arterial occlusive disease			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
anal fistula repair			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ileectomy			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
abortion spontaneous			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
oedema			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pyrexia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
swelling			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
anaphylactic reaction			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
infusion related hypersensitivity reaction			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
panic disorder			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
anastomotic stenosis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
post procedural haemorrhage			

alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
procedural intestinal perforation			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
rib fracture			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
tibia fracture			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
hydrocele			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed ^[1]	1 / 148 (0.68%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
atrial fibrillation			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
angina pectoris			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac arrest			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardio-respiratory arrest			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac failure acute			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
cerebrovascular accident			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
headache			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
loss of consciousness			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myoclonic epilepsy			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
syncope			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
anaemia macrocytic			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
anaemia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
sudden hearing loss			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
anal fistula				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	1 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
abdominal pain upper				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
abdominal pain lower				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
anorectal disorder				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
enterocolonic fistula				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
enteritis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

diarrhoea haemorrhagic alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
gastrointestinal disorder alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
crohn's disease alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	11 / 309 (3.56%) 4 / 16 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
colitis alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
diarrhoea alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
gastrointestinal perforation alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 309 (0.32%) 0 / 1 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
ileal stenosis alternative dictionary used: MedDRA 26.1				

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
ileus				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
inguinal hernia				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
large intestine perforation				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
intestinal perforation				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
intestinal obstruction				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
nausea				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

obstruction gastric alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
pancreatitis acute alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
rectal stenosis alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
small intestinal obstruction alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 309 (0.32%) 0 / 1 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
subileus alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 309 (0.65%) 0 / 2 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
Hepatobiliary disorders bile duct stone alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all cholelithiasis alternative dictionary used: MedDRA 26.1	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		

subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholecystitis acute			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholecystitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholangitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
hydronephrosis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
chondrocalcinosis			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
intervertebral disc degeneration alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
sacroiliitis alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
abdominal abscess alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
anal abscess alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	2 / 309 (0.65%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
abscess limb alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
abscess intestinal alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
covid-19				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	2 / 309 (0.65%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 2	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
covid-19 pneumonia				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
appendicitis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
clostridium difficile colitis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
cellulitis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
gastroenteritis				
alternative dictionary used: MedDRA 26.1				
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

fournier's gangrene alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
clostridium difficile infection alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 309 (0.32%) 1 / 1 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
liver abscess alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
pneumonia aspiration alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
pneumonia alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
peritonitis alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 309 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0		
pelvic abscess alternative dictionary used: MedDRA 26.1				

subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
salpingitis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed ^[2]	0 / 161 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
sepsis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
septic shock			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urosepsis			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	1 / 309 (0.32%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
malnutrition			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 309 (0.00%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Placebo Non-Responders	Mirikizumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	72 / 126 (57.14%)	48 / 85 (56.47%)	319 / 630 (50.63%)
Investigations			
sars-cov-2 test positive			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	1 / 630 (0.16%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
road traffic accident			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 126 (0.00%)	0 / 85 (0.00%)	0 / 630 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
headache			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	6 / 126 (4.76%)	4 / 85 (4.71%)	41 / 630 (6.51%)
occurrences (all)	10	5	58
Blood and lymphatic system disorders			

anaemia alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	10 / 126 (7.94%) 11	11 / 85 (12.94%) 12	43 / 630 (6.83%) 48
General disorders and administration site conditions injection site pain alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all) fatigue alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all) pyrexia alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	8 / 126 (6.35%) 37 10 / 126 (7.94%) 12 5 / 126 (3.97%) 5	0 / 85 (0.00%) 0 2 / 85 (2.35%) 2 6 / 85 (7.06%) 8	20 / 630 (3.17%) 131 23 / 630 (3.65%) 32 27 / 630 (4.29%) 35
Immune system disorders hypersensitivity alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 85 (0.00%) 0	3 / 630 (0.48%) 4
Gastrointestinal disorders abdominal pain alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all) gastrooesophageal reflux disease alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all) crohn's disease alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	7 / 126 (5.56%) 10 1 / 126 (0.79%) 1 21 / 126 (16.67%) 22	8 / 85 (9.41%) 8 0 / 85 (0.00%) 0 7 / 85 (8.24%) 8	26 / 630 (4.13%) 29 11 / 630 (1.75%) 11 17 / 630 (2.70%) 17

diarrhoea alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	8 / 126 (6.35%) 8	3 / 85 (3.53%) 3	33 / 630 (5.24%) 35
vomiting alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	2 / 126 (1.59%) 2	2 / 85 (2.35%) 2	24 / 630 (3.81%) 25
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	10 / 126 (7.94%) 11	4 / 85 (4.71%) 4	41 / 630 (6.51%) 48
Infections and infestations gastroenteritis alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	5 / 126 (3.97%) 5	0 / 85 (0.00%) 0	15 / 630 (2.38%) 18
epstein-barr virus infection alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	0 / 85 (0.00%) 0	0 / 630 (0.00%) 0
covid-19 alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	21 / 126 (16.67%) 22	13 / 85 (15.29%) 14	103 / 630 (16.35%) 106
pustule alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	0 / 85 (0.00%) 0	0 / 630 (0.00%) 0
pharyngotonsillitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	0 / 85 (0.00%) 0	0 / 630 (0.00%) 0
nasopharyngitis			

alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	8 / 126 (6.35%)	2 / 85 (2.35%)	36 / 630 (5.71%)
occurrences (all)	10	2	52
upper respiratory tract infection			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	7 / 126 (5.56%)	9 / 85 (10.59%)	38 / 630 (6.03%)
occurrences (all)	10	10	43

Non-serious adverse events	Ustekinumab	Mirikizumab (Adolescents)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	145 / 309 (46.93%)	5 / 6 (83.33%)	
Investigations			
sars-cov-2 test positive			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	1 / 309 (0.32%)	1 / 6 (16.67%)	
occurrences (all)	1	1	
Injury, poisoning and procedural complications			
road traffic accident			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 309 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Nervous system disorders			
headache			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	15 / 309 (4.85%)	1 / 6 (16.67%)	
occurrences (all)	15	2	
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 26.1			
subjects affected / exposed	15 / 309 (4.85%)	0 / 6 (0.00%)	
occurrences (all)	20	0	
General disorders and administration site conditions			
injection site pain			
alternative dictionary used: MedDRA 26.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>fatigue</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pyrexia</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 309 (3.56%)</p> <p>66</p> <p>7 / 309 (2.27%)</p> <p>7</p> <p>9 / 309 (2.91%)</p> <p>13</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>1 / 6 (16.67%)</p> <p>1</p>	
<p>Immune system disorders</p> <p>hypersensitivity</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 309 (0.65%)</p> <p>2</p>	<p>1 / 6 (16.67%)</p> <p>1</p>	
<p>Gastrointestinal disorders</p> <p>abdominal pain</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>gastrooesophageal reflux disease</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>crohn's disease</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vomiting</p> <p>alternative dictionary used: MedDRA 26.1</p>	<p>10 / 309 (3.24%)</p> <p>14</p> <p>2 / 309 (0.65%)</p> <p>2</p> <p>14 / 309 (4.53%)</p> <p>16</p> <p>12 / 309 (3.88%)</p> <p>16</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>1 / 6 (16.67%)</p> <p>1</p> <p>1 / 6 (16.67%)</p> <p>1</p>	

subjects affected / exposed occurrences (all)	6 / 309 (1.94%) 6	1 / 6 (16.67%) 1	
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	8 / 309 (2.59%) 9	1 / 6 (16.67%) 1	
Infections and infestations gastroenteritis alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	8 / 309 (2.59%) 9	1 / 6 (16.67%) 1	
epstein-barr virus infection alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 309 (0.00%) 0	1 / 6 (16.67%) 1	
covid-19 alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	46 / 309 (14.89%) 48	1 / 6 (16.67%) 1	
pustule alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 309 (0.00%) 0	1 / 6 (16.67%) 1	
pharyngotonsillitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 309 (0.00%) 0	1 / 6 (16.67%) 1	
nasopharyngitis alternative dictionary used: MedDRA 26.1 subjects affected / exposed occurrences (all)	19 / 309 (6.15%) 20	0 / 6 (0.00%) 0	
upper respiratory tract infection alternative dictionary used: MedDRA 26.1			

subjects affected / exposed	22 / 309 (7.12%)	0 / 6 (0.00%)	
occurrences (all)	24	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 April 2020	-Prolonged Screening period by 1 week -Updated inclusion and exclusion criteria -Revised other secondary endpoints
18 December 2020	-Added Provisions for Changes in Study Conduct During Exceptional Circumstances -Updated Prohibited Medications -Revised restrictions on screen failures
01 April 2021	-Updated inclusion criteria
23 February 2022	-Revised objectives and endpoints in response to FDA feedback

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

After enrolling 6 participants, sponsor elected to stop enrollment of adolescents in study AMAM and enroll pediatric participants in a separate, pediatric study. The 6 enrolled participants were allowed to continue treatment and finish the study.

Notes: